Ebola vaccine - ImmunityBio
Latest Information Update: 28 Aug 2023
At a glance
- Originator Etubics Corporation
- Developer ImmunityBio
- Class DNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ebola virus infections
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for preclinical development in Ebola-virus-infections(Prevention) in USA (SC, Injection)
- 05 Jul 2019 Etubics Corporation has patents pending for Ebola vaccine worldwide
- 05 Jul 2019 Preclinical trials in Ebola virus infections (Prevention) in USA (SC) (Etubics pipeline, July 2019)